Hangzhou Defand Therapeutics Co., Ltd. (Defand) announced that it has entered into a research collaboration and licensing agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to jointly discover and develop novel molecular glue degraders (MGDs) targeting multiple therapeutic targets in oncology and immunology. Under the agreement, Defand will leverage its proprietary high‑throughput degrader screening platform to discover MGDs against designated targets, with Roche assuming responsibility for all subsequent preclinical and clinical development and holding exclusive global commercialization rights. Specific financial terms — including the upfront payment amount, milestone payment thresholds, and royalty tiers — were not disclosed in the announcement.
Deal Structure
| Item | Detail |
|---|---|
| Parties | Hangzhou Defand Therapeutics Co., Ltd. (Defand) and Roche |
| Agreement Type | Research collaboration and licensing agreement |
| Therapeutic Focus | Oncology and immunology — multiple targets |
| Technology Platform | Defand’s proprietary high‑throughput degrader screening system |
| Defand Role | Discovery of novel molecular glue degraders (MGDs) against designated targets |
| Roche Role | Preclinical development, clinical development, and exclusive global commercialization |
| Upfront Payment | Amount not disclosed |
| Milestone Payments | Eligible upon achievement of designated R&D stages (specifics not disclosed) |
| Royalties | Tiered royalties on net sales of potential commercialized products (specific tiers not disclosed) |
| Expansion Option | Roche has the option to expand the collaboration to include additional targets |
| Announcement Date | 8 October 2026 |
Technology Platform – Molecular Glue Degraders
- Modality: Molecular glue degraders (MGDs) — a class of small molecules that induce novel protein–protein interactions between a target protein and an E3 ubiquitin ligase, leading to targeted protein degradation via the ubiquitin‑proteasome system.
- Defand’s Platform: A high‑throughput degrader screening system applicable to various types of target proteins, enabling the systematic discovery of MGDs across a broad target landscape.
- Innovation: MGDs represent an emerging modality in drug discovery that has the potential to address previously “undruggable” targets — proteins that lack well‑defined binding pockets amenable to traditional small‑molecule inhibitors or biologics. By inducing degradation rather than inhibition, MGDs can achieve complete functional knockdown of disease‑causing proteins.
- Distinction from PROTACs: While both MGDs and PROTACs achieve targeted protein degradation, molecular glue degraders are typically smaller, more drug‑like molecules that do not require a pre‑existing ligand for the target protein, potentially enabling a broader addressable proteome and more favorable pharmacokinetic properties.
Strategic Rationale
- Roche’s Oncology & Immunology Pipeline: The collaboration aligns with Roche’s ongoing strategy to access cutting‑edge discovery platforms through partnerships with biotech innovators, particularly in protein degradation — one of the most actively pursued modalities in modern drug discovery. Roche’s extensive clinical development infrastructure and global commercial network position it to rapidly advance MGD candidates from discovery through to market.
- Defand’s Platform Validation: Securing a collaboration with Roche, one of the world’s largest pharmaceutical companies, serves as a significant validation of Defand’s MGD discovery platform. The partnership provides Defand with non‑dilutive funding and access to Roche’s development expertise while retaining upside through milestone payments and royalties.
- Multi‑Target Scope: The collaboration’s coverage of multiple targets across oncology and immunology — combined with Roche’s option to expand to additional targets — suggests a broad, platform‑level partnership rather than a single‑asset license, amplifying the potential output of the collaboration.
Market Impact & Outlook
- Molecular Glue Degrader Market Momentum: The targeted protein degradation field has attracted over US$10 billion in cumulative investment and partnership deal value across the industry in recent years, with MGDs increasingly recognized as a next‑generation modality beyond traditional small‑molecule inhibitors and PROTACs. Defand’s collaboration with Roche adds to a growing list of major pharma–biotech MGD partnerships, including deals involving Bristol Myers Squibb, Novartis, and Sanofi.
- “Undruggable” Target Opportunity: MGDs’ ability to degrade proteins without requiring a pre‑defined binding pocket opens access to an estimated ~80% of the human proteome that remains undruggable by conventional approaches. Defand’s high‑throughput platform, if productive, could generate candidates against high‑value targets in oncology and immunology that have eluded traditional drug discovery.
- Platform Economics: While specific financial terms were not disclosed, MGD discovery platform deals of this nature have historically carried upfront payments in the range of tens to hundreds of millions of dollars, with total deal values (including milestones and royalties) reaching into the low billions — reflecting the high optionality value of a broad, multi‑target collaboration.
- Roche’s Degradation Strategy: This collaboration signals Roche’s continued commitment to building a diversified protein degradation portfolio through both internal discovery and external partnerships. Roche’s oncology and immunology franchises — among the largest globally — provide a natural commercial home for successfully developed MGD candidates.
- Chinese Biotech Global Recognition: Defand, as a Hangzhou‑based biotech, joining Roche’s global collaboration network underscores the increasing recognition of Chinese drug discovery platforms by multinational pharmaceutical companies — a trend that has accelerated as Chinese biotechs demonstrate world‑class capabilities in novel modalities including molecular glues, bispecific antibodies, and ADCs.
- Expansion Optionality: Roche’s option to expand the collaboration to additional targets creates a built‑in growth mechanism — if early discovery programs prove productive, the deal could evolve into a much larger strategic partnership, with corresponding increases in milestone and royalty flows to Defand.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the research collaboration between Defand and Roche, including expectations for molecular glue degrader discovery, preclinical and clinical development timelines, and commercial potential. Actual results may differ materially due to risks including the inherent uncertainties of early‑stage drug discovery, the ability to identify viable MGD candidates against designated targets, preclinical and clinical development outcomes, regulatory review timelines, competitive dynamics in the targeted protein degradation field, and the ability of the parties to successfully execute the collaboration. Specific financial terms were not disclosed and may differ materially from market expectations. Investors are advised to exercise caution.-Fineline Info & Tech
